Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Liabilities and Shareholders Equity (2024 - 2025)

Evommune (EVMN) has disclosed Liabilities and Shareholders Equity for 2 consecutive years, with $224.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 195.77% to $224.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $385.5 million, a N/A change, with the full-year FY2025 number at $224.9 million, up 195.77% from a year prior.
  • Liabilities and Shareholders Equity was $224.9 million for Q4 2025 at Evommune, up from $84.5 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $224.9 million in Q4 2025 to a low of $76.1 million in Q4 2024.